Mark J. Pykett

Dr. Mark J. Pykett is Chief Executive Officer of Navidea Biopharmaceuticals. He also served as the company’s President and CEO from April 2011 until May 2013. Dr. Pykett has more than 15 years of pharmaceutical industry executive and operational management, strategic planning and cross-functional drug-development program oversight. Prior to joining Navidea Biopharmaceuticals as Vice President and Chief Development Officer in November 2010, Dr. Pykett served as Founding CEO of Talaris Advisors LLC, a strategic drug-development company serving the biotech industry. Dr. Pykett was President and Chief Operating Officer of Alseres Pharmaceuticals, a clinical-stage biotech firm. Dr. Pykett also held senior executive roles at several public and private biotechnology companies which have focused on therapeutics, diagnostics and medical devices. Dr. Pykett has also served as a Director of several public, private and not-for-profit organizations. He graduated Phi Beta Kappa, summa cum laude, from Amherst College; holds a veterinary degree, Phi Zeta, summa cum laude and a doctorate in molecular biology from the University of Pennsylvania; and received an MBA, Beta Gamma Sigma, from Northeastern University. He completed postdoctoral fellowships at the University of Pennsylvania and Harvard University. Dr. Pykett held an adjunct faculty position at the Harvard School of Public Health from 1997 to 2004, and served on Northeastern University’s Center for Enterprise Growth Corporate Advisory Board.